Bio-Rad Laboratories, Inc. (BIO)
| Market Cap | 9.42B |
| Revenue (ttm) | 2.72B |
| Net Income (ttm) | -153.54M |
| Shares Out | 29.17M |
| EPS (ttm) | -5.82 |
| PE Ratio | n/a |
| Forward PE | 26.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 118,993 |
| Open | 323.20 |
| Previous Close | 324.62 |
| Day's Range | 322.46 - 326.12 |
| 52-Week Range | 261.59 - 509.62 |
| Beta | 0.93 |
| Analysts | Strong Buy |
| Price Target | 481.33 (+49.07%) |
| Earnings Date | Feb 15, 2024 |
About BIO
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for BIO stock is "Strong Buy." The 12-month stock price forecast is $481.33, which is an increase of 49.07% from the latest price.
News
Bio-Rad Labs cuts 2023 revenue growth forecast as biotechs cut spending
Bio-Rad Laboratories on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro challenges, sending the company's shares down...
Bio-Rad Reports Third-Quarter 2023 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced financial results for th...
Bio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for th...
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 2023 Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company's manage...
Bio-Rad Reports Second-Quarter 2023 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the...
Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
HERCULES, Calif., & VENLO, the Netherlands--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the compa...
Bio-Rad Announces New Share Repurchase Program
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that its board of directo...
Bio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the...
Bio-Rad Publishes Corporate Sustainability Report for 2022
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today released its corporate sustainabili...
Bio-Rad to Present Company Overview at Jefferies Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, Pre...
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May - Bio-Rad Laboratories (NYSE:BIO), Accolade (NASDAQ:ACCD)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Bio-Rad to Participate in Fireside Chat During 2023 RBC Capital Markets Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company's manage...
Bio-Rad Reports First-Quarter 2023 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the...
Bio-Rad to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the...
Bio-Rad to Participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company's manage...
Bio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the...
Element Biosciences and Bio-Rad Partner to Deliver Seamless RNA Sequencing Workflow Between Element's AVITI™ System and Bio-Rad's SEQuoia™ Express and SEQuoia™ Complete Stranded RNA Library Prep Kits
SAN DIEGO and HERCULES, Calif. , Feb. 8, 2023 /PRNewswire/ -- Element Biosciences, Inc. — the developer of an innovative DNA sequencing platform disrupting genomics — and Bio-Rad Laboratories, Inc. (N...
Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for t...
Bio-Rad to Present Company Overview at J.P. Morgan 41st Annual Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, P...
Bio-Rad To Participate in Fireside Chat During Credit Suisse's 31st Annual Healthcare Conference
HERCULES, Calif.
Bio-Rad to Report Third Quarter 2022 Financial Results on Thursday, October 27, 2022
HERCULES, Calif.